SPA
TGTX icon

Sherbrooke Park Advisers’s TG Therapeutics TGTX Stock Holding History

Sherbrooke Park Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,363
Closed -$546K – 1159
2024
Q3 		$546K Sell
23,363
-1,299
-5% -$28.4K 0.13% 277
2024
Q2 		$439K Buy
+24,662
New +$394K 0.08% 471
2023
Q4 		– Sell
-12,415
Closed -$104K – 678
2023
Q3 		$104K Buy
+12,415
New +$173K 0.03% 450

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sherbrooke Park Advisers's TGTX Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 23,363 shares — an estimated $546K sold.

Sherbrooke Park Advisers first reported a position in TGTX in Q3 2023 and held it in 3 quarters. The position peaked at $546K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 23,363 TG Therapeutics shares in Q4 2024, an estimated $546K.
  • Sherbrooke Park Advisers first reported a position in TG Therapeutics in Q3 2023 and held it in 3 quarters.
  • Sherbrooke Park Advisers's TG Therapeutics position peaked at $546K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.